Chemoembolization of Hepatocellular Carcinoma

 

 Permissions and Reprints

Abstract

Transarterial chemoembolization (TACE) is the current standard of care for patients with intermediate-stage hepatocellular carcinoma (HCC) and relatively preserved liver function. In a meta-analysis of randomized controlled trials comparing conventional TACE regimens—including the administration of an anticancer-in-oil emulsion followed by embolic agents—versus best supportive care, TACE was shown to improve median survival from 16 to 20 months. Various strategies to improve outcomes for this patient group have become the subject of much ongoing clinical research. The introduction of an embolic drug-eluting bead (DEB) has been shown to substantially improve the pharmacokinetic profile of TACE, providing levels of consistency and repeatability not available with conventional regimens while concomitantly significantly diminishing systemic drug exposure. In randomized trials, DEB-TACE significantly reduced liver toxicity and drug-related adverse events compared with conventional TACE. In this article, technique, indications and contraindications, and clinical outcomes of conventional and DEB-TACE in the management of HCC are reviewed. In addition, scientific background and early clinical experience with the use of combination regimens including TACE and systemically active molecular-targeted agents with antiangiogenic properties are discussed. The combination of DEB-TACE and antiangiogenic therapy represents a potentially powerful approach that is currently undergoing clinical investigation in a phase 3 setting.

• References

• 1 Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55 (2) 74-108
  Google Scholar
• 2 Olsen AH, Parkin DM, Sasieni P. Cancer mortality in the United Kingdom: projections to the year 2025. Br J Cancer 2008; 99 (9) 1549-1554
  CrossrefPubMedGoogle Scholar
• 3 Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138 (2) 513-521 , e1–e6
  CrossrefPubMedGoogle Scholar
• 4 Lencioni R. Chemoembolization for hepatocellular carcinoma. Semin Oncol 2012; 39 (4) 503-509
  CrossrefPubMedGoogle Scholar
• 5 Llovet JM, Di Bisceglie AM, Bruix J , et al; Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100 (10) 698-711
  CrossrefPubMedGoogle Scholar
• 6 Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53 (3) 1020-1022
  CrossrefPubMedGoogle Scholar
• 7 European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56 (4) 908-943
  CrossrefPubMedGoogle Scholar
• 8 Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010; 52 (2) 762-773
  CrossrefPubMedGoogle Scholar
• 9 Varela M, Real MI, Burrel M , et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46 (3) 474-481
  CrossrefPubMedGoogle Scholar
• 10 Lammer J, Malagari K, Vogl T , et al; PRECISION V Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33 (1) 41-52
  CrossrefPubMedGoogle Scholar
• 11 Vogl TJ, Lammer J, Lencioni R , et al. Liver, gastrointestinal and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. AJR Am J Roentgenol 2011; 197 (4) W562-W570
  CrossrefPubMedGoogle Scholar
• 12 Lencioni R. Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy. Crit Rev Oncol Hematol 2012; 83 (2) 216-224
  CrossrefPubMedGoogle Scholar
• 13 Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology 2012; 262 (1) 43-58
  CrossrefPubMedGoogle Scholar
• 14 Lencioni R, de Baere T, Burrel M , et al. Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol 2012; 35 (5) 980-985
  CrossrefPubMedGoogle Scholar
• 15 Kim HC, Chung JW, Park JH , et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma: prospective assessment of the right inferior phrenic artery with C-arm CT. J Vasc Interv Radiol 2009; 20 (7) 888-895
  CrossrefPubMedGoogle Scholar
• 16 Miyayama S, Yamashiro M, Okuda M , et al. Usefulness of cone-beam computed tomography during ultraselective transcatheter arterial chemoembolization for small hepatocellular carcinomas that cannot be demonstrated on angiography. Cardiovasc Intervent Radiol 2009; 32 (2) 255-264
  CrossrefPubMedGoogle Scholar
• 17 Miyayama S, Yamashiro M, Hattori Y , et al. Efficacy of cone-beam computed tomography during transcatheter arterial chemoembolization for hepatocellular carcinoma. Jpn J Radiol 2011; 29 (6) 371-377
  CrossrefPubMedGoogle Scholar
• 18 Forner A, Ayuso C, Varela M , et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are Response Evaluation Criteria in Solid Tumors reliable?. Cancer 2009; 115 (3) 616-623
  CrossrefPubMedGoogle Scholar
• 19 Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30 (1) 52-60
  Article in Thieme ConnectPubMedGoogle Scholar
• 20 Gillmore R, Stuart S, Kirkwood A , et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol 2011; 55 (6) 1309-1316
  CrossrefPubMedGoogle Scholar
• 21 Shim JH, Lee HC, Kim SO , et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology 2012; 262 (2) 708-718
  CrossrefPubMedGoogle Scholar
• 22 Raoul JL, Sangro B, Forner A , et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011; 37 (3) 212-220
  CrossrefPubMedGoogle Scholar
• 23 Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37 (2) 429-442
  CrossrefPubMedGoogle Scholar
• 24 Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2011; 3 (3) CD004787
  PubMedGoogle Scholar
• 25 Ray Jr CE, Haskal ZJ, Geschwind JFH, Funaki BS. The use of transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: a response to the Cochrane Collaboration review of 2011. J Vasc Interv Radiol 2011; 22 (12) 1693-1696
  CrossrefPubMedGoogle Scholar
• 26 Forner A, Llovet JM, Bruix J. Chemoembolization for intermediate HCC: is there proof of survival benefit?. J Hepatol 2012; 56 (4) 984-986
  CrossrefPubMedGoogle Scholar
• 27 Llovet JM, Real MI, Montaña X , et al; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359 (9319) 1734-1739
  CrossrefPubMedGoogle Scholar
• 28 Lo CM, Ngan H, Tso WK , et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35 (5) 1164-1171
  CrossrefPubMedGoogle Scholar
• 29 Song MJ, Park CH, Kim JD , et al. Drug-eluting bead loaded with doxorubicin versus conventional lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a case-control study of Asian patients. Eur J Gastroenterol Hepatol 2011; 23 (6) 521-527
  CrossrefPubMedGoogle Scholar
• 30 Malagari K, Pomoni M, Kelekis A , et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010; 33 (3) 541-551
  CrossrefPubMedGoogle Scholar
• 31 Nicolini A, Martinetti L, Crespi S, Maggioni M, Sangiovanni A. Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. J Vasc Interv Radiol 2010; 21 (3) 327-332
  CrossrefPubMedGoogle Scholar
• 32 Burrel M, Reig M, Forner A , et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol 2012; 56 (6) 1330-1335
  CrossrefPubMedGoogle Scholar
• 33 Woo HY, Jang JW, Choi JY , et al. Tumor doubling time after initial response to transarterial chemoembolization in patients with hepatocellular carcinoma. Scand J Gastroenterol 2010; 45 (3) 332-339
  CrossrefPubMedGoogle Scholar
• 34 Llovet JM, Ricci S, Mazzaferro V , et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359 (4) 378-390
  CrossrefPubMedGoogle Scholar
• 35 Cheng AL, Kang YK, Chen Z , et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10 (1) 25-34
  CrossrefPubMedGoogle Scholar
• 36 Wang B, Xu H, Gao ZQ, Ning HF, Sun YQ, Cao GW. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol 2008; 49 (5) 523-529
  CrossrefPubMedGoogle Scholar
• 37 Virmani S, Rhee TK, Ryu RK , et al. Comparison of hypoxia-inducible factor-1alpha expression before and after transcatheter arterial embolization in rabbit VX2 liver tumors. J Vasc Interv Radiol 2008; 19 (10) 1483-1489
  CrossrefPubMedGoogle Scholar
• 38 Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol 2011; 29 (30) 3960-3967
  CrossrefPubMedGoogle Scholar
• 39 Lencioni R, Llovet JM, Han G , et al. Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): phase II, randomized, double-blind SPACE trial. [abstract LBA154]. J Clin Oncol 2012; 30 (Suppl. 04)
  PubMedGoogle Scholar
• 40 Gish RG, Lencioni R, Di Bisceglie AM, Raoul JL, Mazzaferro V. Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2012; 6 (2) 173-185
  CrossrefPubMedGoogle Scholar